XML 33 R11.htm IDEA: XBRL DOCUMENT
v3.25.2

Cash Equivalents, Investments and Strategic Investments | 6 Months Ended
--- | ---
Jul. 31, 2025
Investments, Debt and Equity Securities [Abstract] |
Cash Equivalents, Investments and Strategic Investments | Cash Equivalents, Investments and Strategic Investments Cash Equivalents and Investments The following is a summary of the Company’s cash equivalents, short-term investments, and long-term investments on the condensed consolidated balance sheets (in thousands):
| July 31, 2025
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Cash equivalents: |  |  |  |  |  |  |
Money market funds | $ | 1,320,540 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,320,540 |
Time deposits | 115,074 |  |  | — |  |  | — |  |  | 115,074 |
U.S. government securities | 52,853 |  |  | — |  |  | (3) |  |  | 52,850 |
Corporate notes and bonds | 10,836 |  |  | — |  |  | (2) |  |  | 10,834 |
Total cash equivalents | 1,499,303 |  |  | — |  |  | (5) |  |  | 1,499,298 |
Investments: |  |  |  |  |  |  |
Corporate notes and bonds | 1,893,404 |  |  | 1,850 |  |  | (1,189) |  |  | 1,894,065 |
U.S. government and agency securities | 572,230 |  |  | 214 |  |  | (656) |  |  | 571,788 |
Commercial paper | 135,245 |  |  | 7 |  |  | (161) |  |  | 135,091 |
Certificates of deposit | 117,920 |  |  | 42 |  |  | (14) |  |  | 117,948 |
Total investments | 2,718,799 |  |  | 2,113 |  |  | (2,020) |  |  | 2,718,892 |
Total cash equivalents and investments | $ | 4,218,102 |  |  | $ | 2,113 |  |  | $ | (2,025) |  |  | $ | 4,218,190 |
| January 31, 2025
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Cash equivalents: |  |  |  |  |  |  |
Money market funds | $ | 1,741,089 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,741,089 |
U.S. government securities | 388,578 |  |  | 92 |  |  | — |  |  | 388,670 |
Time deposits | 113,851 |  |  | — |  |  | — |  |  | 113,851 |
Corporate notes and bonds | 4,466 |  |  | — |  |  | — |  |  | 4,466 |
Commercial paper | 3,064 |  |  | — |  |  | — |  |  | 3,064 |
Total cash equivalents | 2,251,048 |  |  | 92 |  |  | — |  |  | 2,251,140 |
Investments: |  |  |  |  |  |  |
Corporate notes and bonds | 1,559,893 |  |  | 2,177 |  |  | (1,520) |  |  | 1,560,550 |
U.S. government and agency securities | 609,937 |  |  | 528 |  |  | (727) |  |  | 609,738 |
Commercial paper | 307,752 |  |  | 142 |  |  | (38) |  |  | 307,856 |
Certificates of deposit | 187,112 |  |  | 97 |  |  | (4) |  |  | 187,205 |
Total investments | 2,664,694 |  |  | 2,944 |  |  | (2,289) |  |  | 2,665,349 |
Total cash equivalents and investments | $ | 4,915,742 |  |  | $ | 3,036 |  |  | $ | (2,289) |  |  | $ | 4,916,489 |
The Company included $24.2 million and $23.6 million of interest receivable in prepaid expenses and other current assets on the condensed consolidated balance sheets as of July 31, 2025 and January 31, 2025, respectively. The Company did not recognize an allowance for credit losses against interest receivable as of July 31, 2025 and January 31, 2025 because such potential losses were not material. As of July 31, 2025, the contractual maturities of the Company’s available-for-sale marketable debt securities did not exceed 36 months. The estimated fair values of available-for-sale marketable debt securities, classified as short-term or long-term investments on the Company’s condensed consolidated balance sheets, by remaining contractual maturity, are as follows (in thousands):
| July 31, 2025
| Estimated Fair Value
Due within 1 year | $ | 1,705,988 |
Due in 1 year to 3 years | 1,012,904 |
Total | $ | 2,718,892 |
Gross unrealized losses on the Company’s available-for-sale marketable debt securities were not material as of July 31, 2025 and January 31, 2025. For available-for-sale marketable debt securities with unrealized loss positions, the Company does not intend to sell these securities and it is more likely than not that the Company will hold these securities until maturity or a recovery of the cost basis. The decline in fair values of these securities due to credit related factors was not material as of July 31, 2025 and January 31, 2025. Strategic Investments The Company’s strategic investments consist primarily of non-marketable equity securities recorded at cost minus impairment, if any, and adjusted for observable transactions for the same or similar investments of the same issuer (referred to as the Measurement Alternative). The following table presents the Company’s strategic investments by type (in thousands):
|  |  |  |  | July 31, 2025 |  | January 31, 2025
Equity securities: |  |  |  |  |  |  |
Non-marketable equity securities under Measurement Alternative |  |  |  |  | $ | 325,936 |  |  | $ | 281,158 |
Non-marketable equity securities under equity method |  |  |  |  | 5,707 |  |  | 5,491 |
Marketable equity securities |  |  |  |  | 8,385 |  |  | 13,833 |
Debt securities: |  |  |  |  |  |  |
Non-marketable debt securities |  |  |  |  | 11,000 |  |  | 750 |
Total strategic investments—included in other assets |  |  |  |  | $ | 351,028 |  |  | $ | 301,232 |
The following table summarizes the gains and losses associated with the Company’s strategic investments in equity securities (in thousands):
| Three Months Ended July 31, |  | Six Months Ended July 31, |  |
| 2025 |  | 2024 |  | 2025 |  | 2024 |  |
Unrealized losses on non-marketable equity securities under Measurement Alternative: |  |  |  |  |  |  |  |  |
Impairments | $ | (5,000) |  |  | $ | (7,158) |  |  | $ | (31,521) |  |  | $ | (25,911) |  |  |
Net unrealized gains (losses) on marketable equity securities | (980) |  |  | 650 |  |  | (5,448) |  |  | (3,005) |  |  |
Net unrealized losses on strategic investments in equity securities | (5,980) |  |  | (6,508) |  |  | (36,969) |  |  | (28,916) |  |  |
Net realized gains on strategic investments in equity securities sold(1) | 400 |  |  | — |  |  | 1,704 |  |  | 1,713 |  |  |
Total—included in other expense, net | $ | (5,580) |  |  | $ | (6,508) |  |  | $ | (35,265) |  |  | $ | (27,203) |  |  |
________________ (1)Represents the difference between the sale proceeds and the carrying value of the securities at the beginning of the period or the purchase date, if later. The cumulative upward adjustments and the cumulative impairments to the carrying value of the non-marketable equity securities accounted for using the Measurement Alternative held by the Company as of July 31, 2025 were $18.3 million and $60.5 million, respectively.

X
- Definition Cash Equivalents and Investments + References No definition available. + Details
Name: | snow_CashEquivalentsAndInvestmentsTextBlock
Namespace Prefix: | snow_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration